Alerta

SYSTEMS, METHODS, AND COMPOSITIONS FOR THE DETECTION OF MICROBES

Resumen de: AU2024264505A1

Provided are non-naturally occurring systems, methods, and compositions for the detection of microbes. The disclosure relates to the detection of an antigen specific to a microbe, such as a foodborne, an environment-borne, and a bloodborne bacteria, using capture antibody and moiety, detector antibody and moiety, and a light-emitting particle.

一种重组甲型副伤寒沙门菌及其用途

Resumen de: CN121628795A

本发明提供了一株重组表达Vi多糖的甲型副伤寒沙门菌株，以基因工程技术将来自伤寒沙门菌的表达Vi多糖的viaB操纵子克隆到甲型副伤寒沙门菌基因组中，实现Vi多糖在甲型副伤寒沙门菌中的表达；进一步，以一个组成性强启动子(Tac启动子)取代viaB天然启动子实现 Vi 多糖在体外培养条件下的高表达；进一步，将该菌株的msbB基因敲除以降低LPS的酰基化水平，减低LPS毒性；以该菌株制备的囊泡疫苗可诱导针对两种血清型的免疫保护作用。

アジュバントを全く含まないカチオン性多糖ナノ粒子を介して不活性化全細菌を送達するための系を含むワクチン組成物

Resumen de: CN120712079A

The present invention relates to the field of vaccine compositions. The invention more particularly relates to a prophylactic vaccine composition comprising killed intact bacteria intended for use in mammals and birds, said bacteria being wrapped with a cationic agent, in particular cationic nanoparticles.

Lateral flow strip based on loop-mediated isothermal amplification for detection of Salmonella

Resumen de: KR20260030992A

본 발명은 살모넬라 검출을 위한 고리매개등온증폭법 기반 측방유동스트립에 관한 것으로, 보다 상세하게는 고리매개등온증폭(loop-mediated isothermal amplification)용 프라이머 세트; 상기 프라이머 세트에 의해 증폭되는 증폭산물에 특이적으로 결합하는 프로브; 및 측방유동스트립(lateral flow strip);을 포함하는, 살모넬라 속 균을 검출하기 위한 측방유동검사(lateral flow assay) 키트 및 상기 키트를 이용한 살모넬라 속 균의 검출방법에 관한 것이다.

METHOD OF MAKING CHEMILUMINESCENT 1,2-DIOXETANES

Resumen de: WO2026047187A1

The invention relates to a method of making a 1,2-dioxetane, the method comprising reacting a naphthalene endo peroxide (NEPO) with the double bond of an enol ether to form the 1,2-dioxetane. The 1,2-dioxetanes are of great commercial interest for a variety of applications, such as singlet oxygen detection, enzyme detection and pathogen (e.g., Salmonella spp. and Listeria spp.) detection.

BIFIDOBACTERIUM LONGUM SUBSP. LONGUM, AND USE THEREOF IN INHIBITING BACTERIA, RELIEVING COLITIS, AND MITIGATING INFLAMMATORY BONE LOSS

Resumen de: WO2026045196A1

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

SYSTEMS AND METHODS FOR RISK ASSESSMENT FOR ZOONOTIC DISEASE IN ANIMAL POPULATIONS

Resumen de: MX2025014029A

Systems and methods for assessing risk for zoonotic disease, including salmonella, amongst an animal population at a production facility. A user can provide data in response to a plurality of data entry fields that can, at least partially, pertain to a procedure, operation, and/or equipment at the production facility. For each data entry field, the data provided by the user can be assigned a value. The value can correspond to predetermined value of a predetermined response that is identified as corresponding to the user inputted data. The assigned value can be adjusted by a weighted factor, which may correspond to a predicted impact the actions or information reflected by the user inputted data may have on the prevention of zoonotic disease. The assigned and/or adjusted values can be compiled to generate a risk assessment score, which can be used to determine a food safety index score and/or food safety plan.

Salmonella viable bacteria detection system based on deoxyribozyme activation and method thereof

Resumen de: CN121575133A

The invention belongs to the technical field of biological analysis and detection, and particularly discloses a live salmonella detection system and method based on deoxyribozyme activation, the detection system comprises a Sub probe, a deoxyribozyme probe, a hairpin chain probe, a hyperbranched dendritic nano-molecule, a crRNA/Cas12a binary compound, a fluorescent probe and magnetic beads, the hyperbranched dendritic nano-molecule comprises a substrate A, a substrate B and a trigger chain B probe, the substrate A is composed of an A-F chain probe, an A-Q chain probe and an auxiliary chain A probe, and the substrate B is composed of a B-F chain probe, a B-Q chain probe and an auxiliary chain B probe. According to the detection system, ribonuclease H2 released only by metabolism of living salmonella is specifically recognized, and is utilized to activate a Sub-Dz substrate, so that the subsequent reaction can be triggered only by viable bacteria from the source, the problem of dead bacteria interference is effectively solved, and high-sensitivity and high-specificity rapid detection of the viable salmonella is realized.

Anti-diarrhea antibacterial peptide for improving animal intestinal health and preparation method thereof

Resumen de: CN121574184A

The invention belongs to the technical field of biology, and particularly relates to an antibacterial peptide capable of improving animal intestinal health and resisting diarrhea and a preparation method thereof.The novel antibacterial peptide is prepared, and the amino acid sequence of the novel antibacterial peptide is shown as SEQ ID NO: 1; experiments prove that after the cat is raised in a strange environment for one week, the antibacterial peptide can slightly improve the propionic acid and butyric acid levels of the experimental group cat; and the total BCFAs level of the experimental group before and after transportation is lower than that of the blank group. Although the alpha diversity and the beta diversity between an experimental group fed with the antibacterial peptide and a blank group have no significant difference, the feeding of the antibacterial peptide significantly increases the levels of bacteroides, parabacteroides and paraprevotella in the experimental group, and significantly reduces the levels of harmful bacteria such as salmonella and actinomycetes. Therefore, the antibacterial peptide disclosed by the invention can be used for preparing products for improving animal intestinal health and resisting diarrhea, such as feed additives or oral liquid.

一种微生物无标记快速检测系统、方法及其应用

Resumen de: CN121577878A

本发明属于微生物检测技术领域，更具体地是涉及一种微生物无标记快速检测系统、方法及其应用。针对现有生物识别元件进行微生物检测存在的检测通量低、反应效率低、检测样品易交叉污染且依赖大型、精密实验仪器读取信号和专业人员操作而无法在更广泛范围推广应用的问题，本发明提供了一种微生物无标记快速检测系统、方法及其应用，通过设计包含若干容置槽的微生物阵列芯片，可实现在单个芯片上固定多种不同的微生物印迹聚合物。将该微生物阵列芯片应用于微生物无标记快速检测系统便可允许对一份待检样品中的多种微生物进行一次性、并行检测，并可将检测时间缩短至15分钟以内。

ANTI-ETEC ADHESIN PROTEIN ANTIBODIES AND METHODS OF USE

Resumen de: WO2026044176A1

The invention provides anti-enterotoxigenic E. coli (ETEC) adhesin protein antibodies and methods of using the same. One embodiment is an isolated antibody that binds ETEC coli surface antigen 3 (CS3) protein and ETEC coli surface antigen 6 (CS6) protein, wherein the antibody comprises a CS3/CS6 VHH binding domain comprising the following complementary-determining regions (CDRs): (a) a CDR-H1 comprising the amino acid sequence of GFTFEDYA (SEQ ID NO: 19); (b) a CDR-H2 comprising the amino acid sequence of INMSDGST (SEQ ID NO: 20); and (c) a CDR-H3 comprising the amino acid sequence of AANLTGPSGGGLPGYNYDY (SEQ ID NO: 21). Also disclosed are antibodies comprising said CS3/CS6 binding VHH and a binding domain capable of binding to an ETEC adhesin protein selected from colonization factor antigen I adhesin subunit E (CfaE), coli surface antigen 1 (CS1), coli surface antigen 4 (CS4), coli surface antigen 14 (CS14), coli surface antigen 17 (CS17), coli surface antigen 19 (CS19), and coli surface antigen 2 (CS2).

INACTIVATED SALMONELLA VACCINE FORMULATIONS

Resumen de: WO2026043873A1

The present disclosure provides formulations, kits, and vaccines directed to immunization of animals against Salmonella. Methods of usng the formulations, kits, and vaccines for protection of avians against one or more species of Salmonella are also provided. For instance, the formulations, kits, and vaccines can induce an immune response in an animal against a Salmonella infection in which the Salmonella infection is caused by more than one Salmonella group bacterium (e.g., a Group B bacterium, a Group C bacterium, and a Group D bacterium).

ORAL VACCINE AGAINST MULTIPLE DIARRHEA-CAUSING PATHOGENS

Resumen de: EP4699617A1

A vaccine comprising effective amounts of i) E. coli colonization factor antigens comprising CFA/I, CS3, CS5 and CS6 antigens; ii) a heat labile enterotoxin B subunit antigen being an LCTBA protein; and iii) an adjuvant being double mutant (R192G/ L211A) of E. coli heat-labile toxin (dmLT), for use in inducing protective immunity against diarrheal disease caused by Salmonella spp. and/or Shigella spp.

GLYCINAMIDE DERIVATIVES FOR USE IN THE TREATMENT OF SALMONELLOSIS

Resumen de: WO2024218333A1

The present invention relates to compounds of formula (la) that block invasion-associated pathogenicity of Salmonella Typhimurium by inhibiting the activity of the transcription factor HilD. These compounds are useful in the treatment or prophylaxis of Salmonella infections (salmonellosis).

免疫原性组合物

Resumen de: WO2025021695A1

The present invention relates to immunogenic compositions comprising outer membrane vesicles (OMVs) adsorbed to an aluminium hydroxide adjuvant, whereby the aluminium hydroxide adjuvant is quenched. The present invention also relates to the use of the immunogenic compositions for providing protection against diseases caused by Gram-negative bacteria. The present invention also relates to a method for reducing particle aggregation and/or average particle diameter in compositions comprising OMVs and an aluminium hydroxide adjuvant.

鼠疫抗体Fm3及其应用

Resumen de: CN121554580A

本发明公开了鼠疫抗体Fm3及其应用。本发明为本领域提供了一种全新的靶向鼠疫菌F1蛋白的鼠源单克隆抗体，所述抗体能够有效中和鼠疫强毒株和耐药株，具有较好的亲和力和特异性，能够有效抵抗致死剂量的强毒株和耐药株的攻击。本发明为本领域开发鼠疫强毒株和耐药株的治疗药物提供了新策略，具有良好的应用前景。

Lactobacillus reuteri as well as preparation method and application of microbial inoculum of lactobacillus reuteri

Resumen de: CN121555356A

The invention discloses a lactobacillus reuteri and a preparation method and application of a microbial inoculum of the lactobacillus reuteri, the lactobacillus reuteri subsp.reuteri OH114 is preserved in Guangdong Province Microbial Culture Collection Center (GDMCC), the preservation address is No.59 building, No.100 courtyard, Xianlie Middle Road, Guangzhou, the preservation number is GDMCC No.66528, and the preservation time is June 16, 2025. The lactobacillus reuteri newly researched and developed by the invention can effectively inhibit the growth of a plurality of enteropathogenic bacteria such as staphylococcus aureus, escherichia coli, salmonella typhimurium, clostridium difficile, clostridium perfringens, klebsiella pneumoniae, pseudomonas aeruginosa and candida albicans, regulate the balance of intestinal flora, prevent and treat adult diarrhea, and prevent and treat diarrhea. The invention provides a new scheme and way for preventing and treating infectious diarrhea, antibiotic-related diarrhea or irritable bowel syndrome diarrhea.

High-density fermentation process of salmonella bacteriophage RNA polymerase

Resumen de: CN121555461A

The invention discloses a high-density fermentation process of salmonella bacteriophage RNA polymerase, and belongs to the technical field of salmonella. The invention relates to a high-density fermentation process of salmonella phage RNA polymerase. The high-density fermentation process comprises the following steps: S1, preparing a seed solution; s2, seed amplification culture; s3, performing high-density fermentation; s4, performing induced expression; s5, enzyme extraction and purification. The method solves the problems that in the prior art, the culture period completely depends on the splitting speed of the host bacteria, if the period needs to be shortened, the initial bacteriophage infection complex number can only be increased, however, the host bacteria are split too early, and the titer is further reduced. By optimizing a culture medium and a material supplementing strategy, the wet weight of thalli is greatly increased, the enzyme yield per unit fermentation volume is remarkably increased, the enzyme activity ratio and purity of the thalli are increased, the fermentation period is effectively shortened, the production efficiency is improved, and a short-period medium yield mode or a long-period high yield mode can be flexibly switched to meet diversified production requirements.

GENETICALLY MODIFIED BACTERIA FOR GENERATING VACCINES

Resumen de: US20260048107A1

A vaccine is disclosed which comprises a pharmaceutically acceptable carrier and Gramnegative bacteria, genetically modified to express: at least one disease-associated antigen, linked to a signal sequence belonging to a type II secretion system; and the at least one disease-associated antigen linked to a signal sequence belonging to a type III secretion system. Uses thereof are also disclosed.

HOST-DIRECTED THERAPIES FOR SALMONELLA AND FRANCISELLA INFECTION

Resumen de: WO2026039487A1

The invention relates to small molecule compounds that are useful as antimicrobial agents, pharmaceutical compositions comprising the compounds, and the use of the compounds in the treatment of subjects with microbial infections.

Methods for Vaccinating against Salmonella Species

Resumen de: US20260048109A1

Provided herein are methods for vaccinating a subject against a Salmonella species, including typhoidal and non-typhoidal Salmonella species and serovars thereof with an Escherichia coli J5 dLOS/OMP vaccine. The vaccine is cross-reactive with the lipopolysaccharide conserved inner core region of the Salmonella species and cross-protective with the non-typhoidal Salmonella species. Vaccination reduces the likelihood of or prevents the onset of a salmonella infection. Also provided is a method of immunizing against antimicrobial resistant Salmonella species by complementing the J5 dLOS/OMP vaccine with a Salmonella species-specific vaccine.

Pharmaceutical Composition, Preparation Method and Use Thereof

Resumen de: US20260048111A1

The present disclosure relates to the technical field of medicine, and in particular to a pharmaceutical composition, preparation method and use thereof. The pharmaceutical composition includes a first active ingredient, a second active ingredient, and a pharmaceutically acceptable carrier or excipient. The first active ingredient is a microbial agent, including one or more of Staphylococcus aureus, Bordetella pertussis, diphtheria toxoid, tetanus toxoid, Salmonella typhi, and Salmonella paratyphi. The second active ingredient includes polyinosinic acid, polycytidylic acid, and vitamin. The pharmaceutical composition of the present disclosure pertains to an artificial active immunotherapy for tumors. It can “stimulate” the entire immune system, making the therapy of using bacteria to activate the human immune system to kill cancer cells highly stable and reliable. This composition can significantly save and prolong the lives of cancer patients while exhibiting extremely high safety, minimal toxic side effects, and low production costs.

Montmorillonite-based oral intestinal in-situ fermentation system as well as preparation method and application thereof

Resumen de: CN121534203A

The invention provides a montmorillonite-based oral intestinal in-situ fermentation system as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. According to the system, montmorillonite is taken as a carrier, metabolic substrates such as tryptophan and lactulose are loaded between montmorillonite layers through cation replacement, and substrate-related microorganisms such as enterococcus faecalis are adsorbed by utilizing electrostatic interaction, so that an MMT-Bacc-TL complex is obtained. The water impermeability of the montmorillonite endows the system with the ability to resist the severe environment of the gastrointestinal tract, the mucous membrane adhesion characteristic realizes the long-acting retention of the intestinal tract, and beneficial metabolites such as indole and lactic acid are permanently and efficiently synthesized in the intestinal tract by continuously releasing a substrate and forming a bacterial biofilm. The system can remarkably regulate intestinal flora balance, inhibit intestinal inflammation and enhance intestinal barrier integrity, shows curative effects superior to those of existing therapies in diseases such as salmonella typhimurium induced enteritis and candida albicans infection related colitis, is high in oral bioavailability, and can be widely applied to treatment of salmonella typhimurium induced enteritis and candida albicans infection related colitis. And a new effective m

免疫原性组合物

Resumen de: WO2025021712A1

The present invention relates to immunogenic compositions comprising antigens from Salmonella enterica serovar Typhimurium (S. Typhimurium), Salmonella enterica serovar Enteritidis (S. Enteritidis), and Salmonella enterica serovar Typhi (S. Typhi). The present invention further relates to methods and uses of compositions comprising GMMA for boosting an immune response to an S. Typhi antigen, vaccines comprising the immunogenic compositions and methods and uses of the immunogenic compositions.

Salmonella bacteriophage cocktail composition targeting three receptor binding sites and application of salmonella bacteriophage cocktail composition

Nº publicación: CN121538185A 17/02/2026

Solicitante:

UNIV SICHUAN
\u56DB\u5DDD\u5927\u5B66

Resumen de: CN121538185A

The invention discloses a salmonella bacteriophage cocktail composition targeting three receptor binding sites and application thereof, the salmonella bacteriophage cocktail composition comprises a salmonella outer membrane protein ompc and lipopolysaccharide targeting BPSBW1, a salmonella outer membrane protein btuB targeting BPSEW7-1 and a salmonella lipopolysaccharide targeting Phi PhSELC which are all preserved in the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC NO: M 20251569, CCTCC NO: M 20251570 and CCTCC NO: M 20251568, the salmonella outer membrane protein ompc and lipopolysaccharide targeting Phi PhSELC is preserved in the China Center for Type Culture Collection (CCTCC) with the preservation numbers of CCTCC NO: M 20251568, the salmonella the preservation date is July 11, 2025. The bacteriophage combination targeting three receptor binding sites has broad-spectrum and efficient salmonella splitting capacity, provides a bacteriophage source for preventing and treating salmonella in culture and food processing links, and can be used as a green and environment-friendly product or means for preventing and treating salmonella.